Kopran Limited · NSE:KOPRAN
Kopran — Q1 FY2026-27 Earnings Presentation
22 slides from Kopran's earnings presentation, Aug 7, 2026
Slide 1: Exchange filing cover letter for investor presentation
August 07, 2026 The Manager The Manager BSE Limited The National Stock Exchange of India Limited Corporate Relationship Department Exchange Plaza, P. J. Towers, Dalal Street, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 001. Mumbai – 400 051. BSE Scrip Code No. 524280 NSE Symbol: KOPRAN Dear Sir
Slide 2: Corporate Presentation Q1 2026-27
CORPORATE PRESENTATION Q1 - 2026-27
Slide 3: Disclaimer
This quarterly investor presentation has been prepared by Kopran Limited (‘Kopran’) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied, should not
Slide 4: Performance
PERFORMANCE • Financial Highlights • Operational Performance • API • Formulation
Slide 5: Financial Highlights
Q-1 Q-4 Q-1 FY PARTICULARS 2026-27 2025-26 2025-26 2025-26 Revenue from Operations 15,399 23,402 13,522 68,142 EBITDA* 1,588 4,066 1,429 7,825 Finance Costs 328 317 254 1047 Forex Gain/Loss 198 -763 239 -1595 Depreciation 577 452 426 1,747 Tax Expenses 210 648 244 863 Net Profit 670 1,887 745 2,573
Slide 6: Operational Performance
OPERATIONAL ~ PERF ORMA NCE Kopran
Slide 7: APIs Operational Highlights: Segment-wise Revenue Mix
APIs OPERATIONAL HIGHLIGHTS SEGMENT-WISE REVENUE MIX FY 2025-26 (Rs. in Lakhs) Q1 - FY 2026-27 (Rs. in Lakhs) 392 146 43 46 129 27 2,551 1,675 Anti- Diabetic 1024 Anti- Diabetic 6,081 4,580 1037 Antibiotic-Urological 142 Anti- Infective Anti-Hypertensive 388 Anti-Thrombotic Anti-Hypertensive 2,315 C
Slide 8: APIs Operational Highlights: Market-wise Revenue Mix
APIs OPERATIONAL HIGHLIGHTS MARKET-WISE REVENUE MIX FY 2025-26 (Rs. in Lakhs) Q1 - FY 2026-27 (Rs. in Lakhs) 3861 14598 Export Sales Export Sales Local Sales Local Sales 5677 22737 Total Rs. 37,335 Lakhs Total Rs. 9,538 Lakhs
Slide 9: Formulations Operational Highlights: Region-wise Sales Break-up
Formulations OPERATIONAL HIGHLIGHTS REGION-WISE SALES BREAK-UP FY 2025-26 (Rs. in Lakhs) Q1 - FY 2026-27 (Rs. in Lakhs) 1654 2559 697.92 2084.16 Africa Africa 11733 CANADA Canada Latem Latem Middle East and North Africa Middle East and North Africa South Africa South Africa Southeast Asia UK Southea
Slide 10: Formulations Operational Highlights: Product-wise Revenue Mix
Formulations OPERATIONAL HIGHLIGHTS PRODUCT-WISE REVENUE MIX FY 2025-26 (Rs. in Lakhs) Q1 - FY 2026-27 (Rs. in Lakhs) 12130 2573 Non Pen Plant Non Pen Plant Pen Plant Pen Plant 17509 3136 Total Rs. 29,639 Lakhs Total Rs. 5,709 Lakhs
Slide 11: Company Overview
Company Overview • About Us • Business Overview – API • Business Overview – Formulations • Driving Sustainable Growth
Slide 12: A Global Pharmaceutical Company
A GLOBAL PHARMACEUTICAL COMPANY An integrated Pharmaceutical Company, committed to supplying International 50+ Quality Formulations and Active Pharmaceutical Ingredients (APIs) globally. Nations - Export Reach State-of-the-art manufacturing facilities and products with various accreditations and app
Slide 13: API Vertical
API API DEDICATED AND VERSATILE PRODUCT VERTICAL FACILITIES FOR SEGMENT ❖ Anti-hypertensive ❖ Development, manufacturing and ❖ Atenolol ❖ Macrolide sale of diverse APIs and Advanced ❖ Neuromodulator Intermediates ❖ Cephalosporins - Non-Sterile & Sterile ❖ Urological ❖ One of the leaders in Atenolol
Slide 14: Formulations Product Segments
FORMULATIONS PRODUCT SEGMENTS FORMULATIONS VERTICAL ❖ Development and manufacturing of oral solid dosages and dry powder formulations for both Penicillin- and Non-Penicillin-based drugs PENICILLIN-BASED NON-PENICILLIN FINISHED ORAL BASED FINISHED ❖ Catering 100% export markets of both Regulated and
Slide 15: Strategic Imperatives
STRATEGIC IMPERATIVES GROWTH AND SUSTAINABILITY COST LEADERSHIP ❖ Focus on R&D to develop niche, ❖ Development of intermediates for APIs high-value/high-volume APIs and intermediates ❖ Reducing dependence on China to move towards self sufficiency ❖ Capacity expansion ❖ Optimising operational cost ❖
Slide 16: Regulatory Compliance
REGULATORY COMPLIANCE OFFERING BEST-IN-CLASS QUALITY THROUGH STRICT COMPLIANCE The Company maintains highest global regulatory standards FORMULATIONS ACCREDITATIONS of manufacturing and quality at its all plants API ACCREDITATIONS Approved by 15 countries including MHRA (UK), SAPHRA South The plant
Slide 17: Financial Performance
FINANCIA L PERF ORMANCE ~ Kopran "OOo , __ _ _ - - - . SOOo 40oo 30Qo ~OOo 10CJo 0 9~f--====--==::::.:::::.:::.::::.:=.__--=--=:::::::-- - OOo OOo ~ ---- --~
Slide 18: Snapshot
SNAPSHOT EBITDA * (Rs. in LAKHS) SALES/OTHER INCOME (Rs. in LAKHS) 8,739 68,177 8,178 7,790 62,920 63,359 7,441 7,290 55,405 50,980 48,813 5,180 36,013 4,696 15,605 1,588 19-20 20-21 21-22 22-23 23-24 24-25 25-26 Q1-26-27 19-20 20-21 21-22 22-23 23-24 24-25 25-26 Q1-26-27 FINANCE COSTS (Rs. in LAKHS
Slide 19: Building Shareholder Value Year on Year
BUILDING SHAREHOLDER VALUE YEAR ON YEAR EBIT ( Rs. in Lakhs) RoE ( % ) RoCE ( % ) 28.3 25.3 22.4 7,629 7,159 20.1 6,153 6,043 5,731 14.5 3,909 11.8 11.5 9.4 3,738 8.4 9.2 11 6.3 7.6 1,011 4.9 1.5 1.3 19-20 20-21 21-22 22-23 23-24 24-25 25-26 Q1-26-27 19-20 20-21 21-22 22-22 23-24 24-25 25-26 Q1-26-2
Slide 20: Multi-year Financial Summary (Rs. in Lakhs)
(Rs. in Lakhs) PARTICULARS Q1 FY FY FY FY FY FY FY 2026-27 2025-26 2024-25 2023-24 2022-23 2021-22 2020-21 2019-20 Equity Share Capital 4,829 4,829 4,829 4,821 4,821 4,821 4,325 4,325 Other Equity 48,881 48,199 47,006 44,303 39,104 37,796 20,178 14,643 Net Worth 53,709 53,028 51,835 49,125 43,925 42
Slide 21: Board of Directors
BOARD OF DIRECTORS MR. SURENDRA SOMANI MR. VARUN SURENDRA SOMANI MRS. NAMRATA SOMANI CHAIRMAN & MANAGING DIRECTOR DIRECTOR DIRECTOR MR. CHANDRESH GANDHI MRS. MAMTA BIYANI MR. NARAYAN ATAL INDEPENDENT DIRECTOR INDEPENDENT DIRECTOR INDEPENDENT DIRECTOR
Slide 22: About Kopran Limited
ABOUT KOPRAN LIMITED: Kopran Limited is an integrated Pharmaceutical Company, committed to manufacturing and supplying International Quality Formulations and APIs worldwide. Kopran's manufacturing facilities and products have accreditations across all the continents. Research & Development for New P